Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Satsuma Pharmaceuticals

Nasdaq:STSA
Snowflake Description

Excellent balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
STSA
Nasdaq
$294M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. The last earnings update was 29 days ago. More info.


Add to Portfolio Compare Print
  • Satsuma Pharmaceuticals has significant price volatility in the past 3 months.
STSA Share Price and Events
7 Day Returns
5.5%
NasdaqGM:STSA
4.6%
US Pharmaceuticals
2.4%
US Market
1 Year Returns
-
NasdaqGM:STSA
-2%
US Pharmaceuticals
-10%
US Market
STSA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Satsuma Pharmaceuticals (STSA) 5.5% -34.1% -9.9% - - -
US Pharmaceuticals 4.6% -3.1% -7.9% -2% 10% 5.4%
US Market 2.4% -11% -19.4% -10% 9.6% 21.1%
1 Year Return vs Industry and Market
  • No trading data on STSA.
  • No trading data on STSA.
Price Volatility
Industry
5yr Volatility vs Market

STSA Value

 Is Satsuma Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Satsuma Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $16.89.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Satsuma Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Satsuma Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:STSA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-4.80
NasdaqGM:STSA Share Price ** NasdaqGM (2020-04-07) in USD $16.89
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.33x
United States of America Market PE Ratio Median Figure of 2,948 Publicly-Listed Companies 12.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Satsuma Pharmaceuticals.

NasdaqGM:STSA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:STSA Share Price ÷ EPS (both in USD)

= 16.89 ÷ -4.80

-3.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Satsuma Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Satsuma Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Satsuma Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:STSA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.52x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-7.2%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Satsuma Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Satsuma Pharmaceuticals's assets?
Raw Data
NasdaqGM:STSA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $6.64
NasdaqGM:STSA Share Price * NasdaqGM (2020-04-07) in USD $16.89
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.42x
United States of America Market PB Ratio Median Figure of 5,162 Publicly-Listed Companies 1.26x
NasdaqGM:STSA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:STSA Share Price ÷ Book Value per Share (both in USD)

= 16.89 ÷ 6.64

2.55x

* Primary Listing of Satsuma Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Satsuma Pharmaceuticals is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Satsuma Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Satsuma Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

STSA Future Performance

 How is Satsuma Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-7.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Satsuma Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Satsuma Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Satsuma Pharmaceuticals's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Satsuma Pharmaceuticals's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:STSA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:STSA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -7.2%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:STSA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:STSA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 51 -23 1
2023-12-31 19 -54 -58 2
2022-12-31 0 -65 -65 3
2021-12-31 0 -45 -50 3
2020-12-31 0 -41 -46 3
2020-04-08
NasdaqGM:STSA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -30 -28
2019-09-30 -24 -20
2019-06-30 -14 -13
2019-03-31 -11 -10
2018-12-31 -7 -7
2017-12-31 -4 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Satsuma Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Satsuma Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:STSA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Satsuma Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:STSA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.90 -0.90 -0.90 1.00
2023-12-31 -2.46 -1.96 -2.95 2.00
2022-12-31 -2.98 -2.20 -3.45 3.00
2021-12-31 -2.41 -2.32 -2.46 3.00
2020-12-31 -2.53 -2.18 -2.90 3.00
2020-04-08
NasdaqGM:STSA Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -4.80
2019-09-30 -11.20
2019-06-30 -11.81
2019-03-31 -9.57
2018-12-31 -7.15
2017-12-31 -9.26

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Satsuma Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Satsuma Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Satsuma Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

STSA Past Performance

  How has Satsuma Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Satsuma Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Satsuma Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Satsuma Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Satsuma Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Satsuma Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Satsuma Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:STSA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -28.18 4.69 24.20
2019-09-30 -19.71 2.89 17.00
2019-06-30 -13.04 2.08 10.94
2019-03-31 -10.19 1.58 8.69
2018-12-31 -7.35 1.08 6.43
2017-12-31 -5.17 0.75 4.19

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Satsuma Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Satsuma Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Satsuma Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Satsuma Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Satsuma Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

STSA Health

 How is Satsuma Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Satsuma Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Satsuma Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Satsuma Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Satsuma Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 23.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Satsuma Pharmaceuticals Company Filings, last reported 3 months ago.

NasdaqGM:STSA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 115.34 4.93 107.70
2019-09-30 118.12 5.06 118.95
2019-06-30 52.15 5.03 55.04
2019-03-31 52.15 5.03 55.04
2018-12-31 -0.48 4.97 5.21
2017-12-31 0.10 0.09 1.66
  • Satsuma Pharmaceuticals's level of debt (4.3%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Satsuma Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Satsuma Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • Satsuma Pharmaceuticals has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 81.5% each year.
X
Financial health checks
We assess Satsuma Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Satsuma Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

STSA Dividends

 What is Satsuma Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Satsuma Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought $2,000 of Satsuma Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Satsuma Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Satsuma Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:STSA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:STSA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Satsuma Pharmaceuticals has not reported any payouts.
  • Unable to verify if Satsuma Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Satsuma Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Satsuma Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Satsuma Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Satsuma Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Satsuma Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Satsuma Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

STSA Management

 What is the CEO of Satsuma Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Kollins
COMPENSATION $568,180
AGE 56
TENURE AS CEO 3.8 years
CEO Bio

Mr. John A. Kollins, MBA, has been Director, President and Chief Executive Officer of Satsuma Pharmaceuticals, Inc since July 2016. He served as Chief Business Officer and Senior Vice President of Transcept Pharmaceuticals, Inc since June 01, 2012 until October 2014. He co-founded Satsuma Pharmaceuticals in July 2016. Prior to joining Transcept, Mr. Kollins was the managing director and founder of Parnassus Advisors from September 2011 to May 2012 and was a managing director and senior advisor at Locust Walk Partners, from December 2009 to September 2011. He served as Chief Business Officer and Senior Vice President at Paratek Pharmaceuticals, Inc. till October 30, 2014. He served as Vice President of Business Development at Evotec (US), Inc. since January 2003. Mr. Kollins served as the Chief Executive Officer of Oxigene Inc. from October 2008 to October 7, 2009 and served as its President until October 7, 2009. Mr. Kollins served as the Chief Operating Officer of Oxigene Inc. from July 2008 to October 2008. Mr. Kollins has also served in executive, business development and product management roles at various biopharmaceutical companies, including CovX, Renovis and Elan Pharmaceuticals. Mr. Kollins served as the Chief Business Officer and Senior Vice President of Oxigene Inc., from March 1, 2007 to October 2009. He has over 20 years of pharmaceutical and biotechnology industry experience, specifically in strategic marketing, new product development and business development. Prior to OXiGENE, Mr. Kollins served as an Independent Consultant from February 2005 to 2007. In his extensive career, he is particularly successful in establishing collaborative and productive R & D partnerships. His clients have included GRT Capital Partners, LLC's health care fund, GRT Health Care, LP, Entelos, Inc., CovX and several other private and publicly-held biopharmaceutical companies. From October 2004 to February 2005, he served as the Chief Business Officer of CovX Research LLC. Mr. Kollins served as an Advisor of CovX since February 2005 and works with health care investment and operating companies, including GRT Capital Partners, and several development-stage biopharmaceutical companies. He served as the Vice President of Business Development at Renovis Inc., from January 2003 to January 2004 and its Consultant from January 2004 to October 2004. From 2000 to 2002, Mr. Kollins served as Vice President of Business Development at SurroMed, Inc., from April 2000 to July 2002, where he helped develop its business strategy and established its initial strategic partnerships with pharmaceutical and biotechnology companies and as an Advisor to the Chief Executive Officer of SurroMed from July 2002 to January 2003. Mr. Kollins serves as Scientific Advisor of Ingenium Pharmaceuticals GmbH. Mr. Kollins served as a Director of Business Development of Elan Corporation from 1997 to 1999 and as an Associate Director of Business Development since 1996, where he was responsible for strategic licensing and partnership transactions. He served as an Associate Director of Product Management of Athena Neurosciences, Inc. (acquired by Elan Corporation) from 1995 to 1996 and also served as its Senior Product Manager from 1994 to 1995. Mr. Kollins served as the Product Manager of Immunex Corporation from 1989 to 1993 and as Business Analyst since 1989. He serves as the Chairman of External Advisory Board at CovX. He serves as Director of Symphony ViDA, Inc. He serves as Member of Advisory Board of CovX Research LLC. He served as Director of Oxigene Inc. from October 2008 to October 7, 2009. Mr. Kollins earned a BSE degree (mechanical engineering and materials science) magna cum laude from Duke University and an MBA with honors from the University of Virginia's Darden School.

CEO Compensation
  • Insufficient data for John to compare compensation growth.
  • John's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Satsuma Pharmaceuticals management team in years:

2.8
Average Tenure
55
Average Age
  • The tenure for the Satsuma Pharmaceuticals management team is about average.
Management Team

John Kollins

TITLE
President
COMPENSATION
$568K
AGE
56
TENURE
3.8 yrs

Detlef Albrecht

TITLE
Chief Medical Officer
COMPENSATION
$476K
AGE
58
TENURE
2.8 yrs

Tom O'Neil

TITLE
Chief Financial Officer
AGE
54
TENURE
1.3 yrs

Mic Iwashima

TITLE
VP & Head of Operations
AGE
41
TENURE
3.3 yrs

Rob Schultz

TITLE
VP & Head of CMC
AGE
55
TENURE
2.8 yrs

Shannon Strom

TITLE
VP & Head of Regulatory Affairs
AGE
43
TENURE
1.9 yrs

Rob Janosky

TITLE
Chief Commercial Officer
TENURE
0.1 yrs

Alan Mendelson

TITLE
Secretary
AGE
69
Board of Directors Tenure

Average tenure and age of the Satsuma Pharmaceuticals board of directors in years:

3.3
Average Tenure
56
Average Age
  • The tenure for the Satsuma Pharmaceuticals board of directors is about average.
Board of Directors

Heath Lukatch

TITLE
Chairman of the Board
AGE
52
TENURE
3.3 yrs

John Kollins

TITLE
President
COMPENSATION
$568K
AGE
56
TENURE
3.8 yrs

Tom King

TITLE
Independent Director
COMPENSATION
$42K
AGE
64
TENURE
2.6 yrs

Ken Takanashi

TITLE
Independent Director
AGE
55
TENURE
3.8 yrs

Lisa Sandoval

TITLE
Independent Director
AGE
57
TENURE
0.9 yrs

Mike Riebe

TITLE
Independent Director
COMPENSATION
$33K
AGE
59
TENURE
2.5 yrs

Raj Shah

TITLE
Independent Director
AGE
42
TENURE
3.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
18. Sep 19 Buy TPG Capital, L.P. Company 17. Sep 19 17. Sep 19 100,000 $15.00 $1,500,000
17. Sep 19 Buy Shin Nippon Biomedical Laboratories, Ltd. Company 17. Sep 19 17. Sep 19 233,333 $15.00 $3,499,995
17. Sep 19 Buy RA Capital Management, L.P. Company 17. Sep 19 17. Sep 19 1,333,333 $15.00 $19,999,995
X
Management checks
We assess Satsuma Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Satsuma Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

STSA News

Simply Wall St News

STSA Company Info

Description

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.

Details
Name: Satsuma Pharmaceuticals, Inc.
STSA
Exchange: NasdaqGM
Founded: 2016
$293,582,773
17,382,047
Website: http://www.satsumarx.com
Address: Satsuma Pharmaceuticals, Inc.
400 Oyster Point Boulevard,
Suite 221,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM STSA Common Shares Nasdaq Global Market US USD 13. Sep 2019
MUN 1LV Common Shares Boerse Muenchen DE EUR 13. Sep 2019
Number of employees
Current staff
Staff numbers
17
Satsuma Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 11:43
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/04/06
Last earnings filing: 2020/03/10
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.